Takeda’s Vyvanse (lisexamfetamine dimesylate) Chewable Tablet Receives Health Canada’s Approval for the Treatment of Patients with Attention-Deficit/Hyperactivity Disorder Aged≥ 6yrs.

Shots:

• The approval is based on the clinical study results assessing the bioavailability of chewable Vyvanse tablets vs Vyvanse capsule formulation post 60mg (qd) administration under fasting condition in 18 adult patients with ADHD
• Vyvanse chewable tablets are available in multiple doses i.e, 10 mg/20 mg/30 mg/40 mg/50 mg/60 mg and are the most preferred formulation among school-aged children, with its expected availability in Canada in H2’19
• Vyvanse is a CNS stimulant helps in increasing attention & decreasing impulsiveness and hyperactivity in patients with ADHD and has received Health Canada’s approval for binge eating disorder in adults and ADHD in children aged 6-12 yrs. in 2016 & 2009 respectively

Click here to read full press release/ article | Ref: Takeda | Image: Takeda